Scientists Engineer Bacteria to Transform Plastic Waste into Parkinson's Drug L-DOPA
Key Insights
University of Edinburgh researchers have successfully engineered E. coli (search) bacteria to convert plastic bottles into L-DOPA, a frontline medication for Parkinson's disease (search).
The breakthrough process achieved 5.0 g/L production titre with 84% conversion efficiency from industrial waste, representing the first biological transformation of plastic waste into a neurological therapeutic.
The two-strain microbial system overcomes key biochemical challenges and offers a more sustainable alternative to traditional fossil fuel-based pharmaceutical manufacturing.
Scientists at the University of Edinburgh have achieved a groundbreaking feat by engineering bacteria to transform discarded plastic bottles into L-DOPA, a crucial medication for treating Parkinson's disease (search). This pioneering research, published in Nature Sustainability, represents the first time a natural biological process has been engineered to convert plastic waste into a therapeutic for neurological disease.
Revolutionary Bacterial Engineering Process
The research team, led by Professor Stephen Wallace, engineered E. coli (search) bacteria to convert polyethylene terephthalate (PET) - the plastic commonly used in food and drink packaging - into L-DOPA through a sophisticated biological pathway. The process begins by breaking down PET waste into terephthalic acid (search) (TPA), which is then transformed into the therapeutic compound through a series of engineered biological reactions.
The breakthrough required overcoming significant biochemical challenges. Initial testing revealed two major bottlenecks: bacteria struggled to transport TPA across cell membranes at neutral pH, and a pathway intermediate called protocatechuate (search) (PCA) inhibited the final enzyme through feedback inhibition. The team addressed the transport issue by expressing the TpaK transporter (search) protein from Rhodococcus jostii, which significantly improved uptake.
Two-Strain Solution for Enhanced Efficiency
To overcome the enzyme inhibition problem, researchers developed an innovative two-strain microbial system. One bacterial strain converts TPA into catechol, while a second strain transforms catechol into L-DOPA. This separation eliminated the feedback inhibition that occurred when PCA concentrations exceeded 2 mM, which completely eliminated detectable L-DOPA production.
The optimized system achieved remarkable results, producing L-DOPA at a titre of 5.0 g/L with 84% conversion efficiency from industrial waste in a two-step workflow. When tested with real-world materials, including post-consumer plastic bottles, the process achieved a 49% conversion rate and yielded 193 mg of L-DOPA as a solid salt - equivalent to several clinical doses for early-stage Parkinson's disease (search).
Environmental and Economic Implications
The research addresses two critical global challenges simultaneously: the plastic waste crisis and sustainable pharmaceutical manufacturing. With approximately 50 million tonnes of PET waste produced annually, and over 400 million metric tons of plastic waste generated globally each year, this technology offers a pathway to transform environmental pollutants into valuable medical resources.
Professor Wallace emphasized the broader implications: "If we can create medicines for neurological disease from a waste plastic bottle, it's exciting to imagine what else this technology could achieve. Plastic waste is often seen as an environmental problem, but it also represents a vast, untapped source of carbon."
Carbon-Neutral Production Potential
The researchers also demonstrated the potential for carbon-neutral production by incorporating the microalga Chlamydomonas reinhardtii to capture carbon dioxide generated during the process. The algae reduced CO2 levels in the culture headspace to undetectable levels within 12 hours, supporting a proof-of-concept carbon-neutral production cycle.
Industrial Applications and Future Development
The research was conducted at the new £14 million Carbon-Loop Sustainable Biomanufacturing Hub (search) (C-Loop), which aims to transform UK manufacturing by converting industrial waste into sustainable chemicals and materials. The team believes this breakthrough could pave the way for a bio-upcycling industry producing not only pharmaceuticals but also flavourings, fragrances, cosmetics, and industrial chemicals.
Dr. Liz Fletcher of the Industrial Biotechnology Innovation Centre (search) noted: "Turning plastic bottles into a Parkinson's drug isn't just a creative recycling idea, it's a way of redesigning processes that work with nature to deliver real-world benefits."
Next Steps Toward Commercialization
Having demonstrated the technology's viability on a small scale, researchers are now focused on advancing toward industrial application. This involves further optimizing the process, improving scalability, and conducting comprehensive assessments of environmental and economic performance.
Professor Charlotte Deane, executive chair of UKRI EPSRC (search), highlighted the research's significance: "By converting discarded plastic into a treatment for Parkinson's disease (search), the University of Edinburgh team has demonstrated how carbon that would otherwise be lost to landfill or pollution can be turned into high value products that improve lives."
The study represents a significant step toward sustainable pharmaceutical manufacturing, offering a more environmentally friendly alternative to traditional fossil fuel-based chemical synthesis while addressing the growing global plastic waste problem.